Chromadex Corp (CDXC)

$3.07

-0.12

(-3.76%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $3.05
    $3.28
    $3.07
    downward going graph

    0.81%

    Downside

    Day's Volatility :7.16%

    Upside

    6.4%

    downward going graph
  • $1.25
    $4.65
    $3.07
    downward going graph

    59.28%

    Downside

    52 Weeks Volatility :73.12%

    Upside

    33.98%

    downward going graph

Returns

PeriodChromadex CorpSector (Health Care)Index (Russel 2000)
3 Months
-7.27%
6.5%
0.0%
6 Months
108.5%
7.1%
0.0%
1 Year
98.14%
9.8%
0.0%
3 Years
-66.49%
14.2%
-20.2%

Highlights

Market Capitalization
242.5M
Book Value
$0.38
Earnings Per Share (EPS)
-0.05
PEG Ratio
0.0
Wall Street Target Price
6.9
Profit Margin
-4.24%
Operating Margin TTM
-3.3%
Return On Assets TTM
-5.06%
Return On Equity TTM
-12.39%
Revenue TTM
83.2M
Revenue Per Share TTM
1.11
Quarterly Revenue Growth YOY
-1.7999999999999998%
Gross Profit TTM
42.8M
EBITDA
-3.4M
Diluted Eps TTM
-0.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.01
EPS Estimate Next Year
0.06
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Chromadex Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 124.76%

Current $3.07
Target $6.90

Company Financials

FY18Y/Y Change
Revenue
31.6M
↑ 48.84%
Net Income
-33.3M
↑ 192.82%
Net Profit Margin
-105.57%
↓ 51.91%
FY19Y/Y Change
Revenue
46.3M
↑ 46.69%
Net Income
-31.5M
↓ 5.54%
Net Profit Margin
-67.99%
↑ 37.58%
FY20Y/Y Change
Revenue
59.3M
↑ 28.01%
Net Income
-18.5M
↓ 41.27%
Net Profit Margin
-31.19%
↑ 36.8%
FY21Y/Y Change
Revenue
67.4M
↑ 13.82%
Net Income
-25.6M
↑ 38.27%
Net Profit Margin
-37.89%
↓ 6.7%
FY22Y/Y Change
Revenue
72.1M
↑ 6.82%
Net Income
-14.4M
↓ 43.46%
Net Profit Margin
-20.05%
↑ 17.84%
FY23Y/Y Change
Revenue
83.6M
↑ 15.99%
Net Income
-4.9M
↓ 65.82%
Net Profit Margin
-5.91%
↑ 14.14%
Q4 FY22Q/Q Change
Revenue
21.0M
↑ 23.05%
Net Income
673.0K
↓ 38.54%
Net Profit Margin
3.21%
↓ 3.21%
Q1 FY23Q/Q Change
Revenue
22.6M
↑ 7.43%
Net Income
-1.3M
↓ 297.62%
Net Profit Margin
-5.9%
↓ 9.11%
Q2 FY23Q/Q Change
Revenue
20.3M
↓ 9.9%
Net Income
-2.2M
↑ 64.74%
Net Profit Margin
-10.78%
↓ 4.88%
Q3 FY23Q/Q Change
Revenue
19.5M
↓ 4.07%
Net Income
-959.0K
↓ 56.23%
Net Profit Margin
-4.92%
↑ 5.86%
Q4 FY23Q/Q Change
Revenue
21.2M
↑ 8.73%
Net Income
114.0K
↓ 111.89%
Net Profit Margin
0.54%
↑ 5.46%
Q1 FY24Q/Q Change
Revenue
22.2M
↑ 4.52%
Net Income
-492.0K
↓ 531.58%
Net Profit Margin
-2.22%
↓ 2.76%
FY18Y/Y Change
Total Assets
42.2M
↓ 32.67%
Total Liabilities
15.1M
↑ 69.34%
FY19Y/Y Change
Total Assets
40.2M
↓ 4.7%
Total Liabilities
19.8M
↑ 31.54%
FY20Y/Y Change
Total Assets
38.4M
↓ 4.69%
Total Liabilities
21.9M
↑ 10.77%
FY21Y/Y Change
Total Assets
57.8M
↑ 50.79%
Total Liabilities
26.1M
↑ 19.05%
FY22Y/Y Change
Total Assets
54.1M
↓ 6.54%
Total Liabilities
25.4M
↓ 2.79%
FY23Y/Y Change
Total Assets
55.0M
↑ 1.68%
Total Liabilities
26.5M
↑ 4.42%
Q4 FY22Q/Q Change
Total Assets
54.1M
↑ 18.38%
Total Liabilities
25.4M
↑ 3.02%
Q1 FY23Q/Q Change
Total Assets
53.8M
↓ 0.53%
Total Liabilities
25.8M
↑ 1.44%
Q2 FY23Q/Q Change
Total Assets
53.2M
↓ 1.11%
Total Liabilities
26.0M
↑ 1.05%
Q3 FY23Q/Q Change
Total Assets
53.5M
↑ 0.59%
Total Liabilities
26.2M
↑ 0.59%
Q4 FY23Q/Q Change
Total Assets
55.0M
↑ 2.77%
Total Liabilities
26.5M
↑ 1.27%
Q1 FY24Q/Q Change
Total Assets
54.1M
↓ 1.61%
Total Liabilities
25.1M
↓ 5.21%
FY18Y/Y Change
Operating Cash Flow
-20.9M
↑ 113.26%
Investing Cash Flow
-1.8M
↓ 138.57%
Financing Cash Flow
-90.0K
↓ 100.18%
FY19Y/Y Change
Operating Cash Flow
-20.4M
↓ 2.24%
Investing Cash Flow
-249.0K
↓ 85.97%
Financing Cash Flow
16.9M
↓ 18860.0%
FY20Y/Y Change
Operating Cash Flow
-10.6M
↓ 48.14%
Investing Cash Flow
-165.0K
↓ 33.73%
Financing Cash Flow
8.7M
↓ 48.77%
FY21Y/Y Change
Operating Cash Flow
-24.2M
↑ 127.95%
Investing Cash Flow
-409.0K
↑ 147.88%
Financing Cash Flow
36.1M
↑ 317.27%
FY22Y/Y Change
Operating Cash Flow
-15.1M
↓ 37.52%
Investing Cash Flow
-334.0K
↓ 18.34%
Financing Cash Flow
7.7M
↓ 78.79%
Q4 FY22Q/Q Change
Operating Cash Flow
-328.0K
↓ 91.23%
Investing Cash Flow
-172.0K
↑ 230.77%
Financing Cash Flow
7.7M
↓ 42761.11%
Q1 FY23Q/Q Change
Operating Cash Flow
2.8M
↓ 951.22%
Investing Cash Flow
-91.0K
↓ 47.09%
Financing Cash Flow
-1000.0
↓ 100.01%
Q2 FY23Q/Q Change
Operating Cash Flow
3.3M
↑ 17.48%
Investing Cash Flow
-5.0K
↓ 94.51%
Financing Cash Flow
-10.0K
↑ 900.0%

Technicals Summary

Sell

Neutral

Buy

Chromadex Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Chromadex Corp
Chromadex Corp
19.48%
108.5%
98.14%
-66.49%
-61.93%
Kraft Heinz Company, The
Kraft Heinz Company, The
3.0%
-10.53%
-8.44%
-15.76%
4.52%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
10.49%
8.24%
-16.86%
-12.43%
-8.02%
Hormel Foods Corporation
Hormel Foods Corporation
5.36%
2.74%
-21.98%
-32.63%
-23.05%
General Mills, Inc.
General Mills, Inc.
2.59%
2.05%
-13.08%
10.97%
22.73%
Kellanova
Kellanova
-0.17%
4.64%
-15.19%
-9.44%
-2.47%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Chromadex Corp
Chromadex Corp
NA
NA
0.0
-0.01
-0.12
-0.05
NA
0.38
Kraft Heinz Company, The
Kraft Heinz Company, The
14.79
14.79
1.02
2.77
0.06
0.04
0.05
40.79
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
27.09
27.09
2.48
2.86
0.14
0.05
0.02
19.83
Hormel Foods Corporation
Hormel Foods Corporation
22.51
22.51
2.96
1.6
0.1
0.05
0.04
14.39
General Mills, Inc.
General Mills, Inc.
15.2
15.2
1.98
4.5
0.25
0.07
0.04
16.81
Kellanova
Kellanova
24.25
24.25
2.93
0.79
0.21
0.05
0.04
9.24
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Chromadex Corp
Chromadex Corp
Buy
$242.5M
-61.93%
NA
-4.24%
Kraft Heinz Company, The
Kraft Heinz Company, The
Buy
$41.1B
4.52%
14.79
10.62%
Mccormick & Company, Incorporated
Mccormick & Company, Incorporated
Hold
$19.9B
-8.02%
27.09
11.07%
Hormel Foods Corporation
Hormel Foods Corporation
Hold
$17.3B
-23.05%
22.51
6.37%
General Mills, Inc.
General Mills, Inc.
Hold
$36.7B
22.73%
15.2
12.57%
Kellanova
Kellanova
Hold
$19.6B
-2.47%
24.25
7.09%

Insights on Chromadex Corp

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 19.49M → 22.15M (in $), with an average increase of 6.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 114.0K → -492.0K (in $), with an average decrease of 531.6% per quarter

  • Vs GIS

    In the last 3 years, Chromadex Corp has experienced a drawdown of -66.5%, however General Mills, Inc. resisted the overall trend and outperformed by 50.7%

Institutional Holdings

  • Vanguard Group Inc

    4.04%

  • Tieton Capital Management, LLC

    4.00%

  • ICONIQ Capital, LLC

    1.72%

  • BlackRock Inc

    1.20%

  • Millennium Management LLC

    0.77%

  • Geode Capital Management, LLC

    0.74%

Company Information

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).

Organization
Chromadex Corp
Employees
106
CEO
Mr. Frank Louis Jaksch Jr.
Industry
Process Industries

Discover More

FAQs